Eleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference
November 09 2017 - 8:00AM
Business Wire
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing novel product candidates based
on its Targeted Protein Therapeutics (TPTs) platform, today
announced that Stephen Hurly, President and Chief Executive
Officer, will present a company overview at the Stifel 2017
Healthcare Conference in New York on Wednesday, November 15, 2017
at 3:30 p.m. EST.
A live webcast can be accessed from the Investors & Media
section of Eleven's website, www.elevenbio.com. An archived replay
of the webcast will be available on the Company's website for 90
days after the conference.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology
company advancing novel product candidates based upon the Company’s
targeted protein therapeutics (TPTs) platform. The Company’s TPTs
incorporate a tumor-targeting antibody fragment and a protein
cytotoxic payload into a single protein molecule in order to
achieve focused tumor cell killing. The Company believes its TPT
approach offers significant advantages in treating cancer over
existing antibody drug conjugate technologies. The Company believes
its TPTs provide effective tumor targeting with broader cancer
cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistant mechanisms. Additionally, the Company believes that its
TPT’s cancer cell-killing properties promote an anti-tumor immune
response that will potentially combine well with immune oncology
drugs such as checkpoint inhibitors. For more information, please
refer to the Company’s website at www.elevenbio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109005480/en/
Stern Investor Relations, Inc.Michael Schaffzin,
212-362-1200michael@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024